Alexey Danilov, M.D., Ph.D.

1-800-826-4673
Alexey Danilov Bio
Hematologist-Oncologist
4.8 (133 RATINGS)
Clinical Expertise
Hematology-Oncology
Hematology & Hematopoietic Cell Transplantation
Lymphoma
Research Area
Lymphoma Malignancies
Appointments
Associate Director, Toni Stephenson Lymphoma Center
Professor, Division Of Lymphoma, Department Of Hematology & Hematopoietic Cell Transplantation
Clinical Teams
Hematology & Hematopoietic Cell Transplantation
Lymphoma
Research Teams
Lymphoma Research

"In oncology today, we are given great opportunities to make a lot of positive impact on the lives of our patients."

Alexey Danilov, M.D., Ph.D., chose oncology as a career because of its breadth and potential. Oncology, he says, "touches all areas of general medicine" and is a most exciting field because of the many new treatments now emerging.

A board-certified clinician and talented researcher, Dr. Danilov focuses on blood cancers, including chronic lymphocytic leukemia and many forms of lymphoma. He is a Leukemia & Lymphoma Society Scholar in Clinical Research.

A native of Russia, Dr. Danilov earned his medical degree and Ph.D. at Yaroslavl State Medical Academy. He continued his training with a residency at Brown University in Providence, Rhode Island, and a fellowship at Tufts Medical Center in Boston.

In his role of an Associate Director, Toni Stephenson Lymphoma Center at City of Hope, Dr. Danilov directs an effort in experimental therapeutics in B-cell malignancies. He received peer-reviewed funding from the National Cancer Institute, Leukemia and Lymphoma Society, American Society of Hematology, and Lymphoma Research Foundation, and serves as Translational Medicine Chair of the SWOG Lymphoma Committee, thus participating in drug discovery on a global scale.

An ideal fit for City of Hope, Dr. Danilov's lab is funded by the National Cancer Institute, Leukemia and Lymphoma Society and American Society of Hematology and concentrates on "bench to bedside" medicine, where preclinical findings lead to early phase clinical trials, ultimately translating into real treatments for real patients.

Visit the Danilov Lab
Location
Education & Experience
Board Certifications

  • 2012, American Board of Internal Medicine, Hematology

  • 2010, American Board of Internal Medicine, Medical Oncology

  • 2007, American Board of Internal Medicine, Internal Medicine

Degrees

  • 2000, Ph.D., Yaroslavl Medical Academy, Russia

  • 1997, M.D., summa cum laude, Yaroslavl Medical Academy, Russia

Fellowship

  • 2007-2010, Hematology/Oncology, Tufts Medical Center, Boston, Massachusetts

Residency

  • 2004-2007, Medicine, Brown University School of Medicine, Providence, Rhode Island

Internship

  • 2004-2005, Medicine, Brown University School of Medicine, Providence, RI

Professional Experience

  • 2020-Present, Professor, Division of Lymphoma, Department of Hematology & Hematopoietic Cell Transplantation

  • Associate Director, Toni Stephenson Lymphoma Center, City of Hope, Duarte, CA

  • 2020-Present, Translational Medicine Chair, SWOG Lymphoma

  • 2014-2020, Assistant & Associate Professor of Medicine, Hematology - Oncology, OHSU, Portland, OR

  • 2010-2014, Assistant Professor of Medicine, Hematology/Oncology, Dartmouth-Hitchcock Medical Center, Lebanon, NH

  • 2001-2004, Research Scholar, Tufts University School of Medicine, Boston, MA

  • 2000-2001, Instructor, Department of Medicine, Yaroslavl Medical Academy, Russia

  • 1998-1999, Instructor, Department of Pathophysiology, Yaroslavl Medical Academy, Russia

Research
The Danilov Lab focuses its attention on drug resistance in lymphoma, with emphasis on key signaling pathways (TNF receptor and NFκB signaling). Using stromal co-cultures, the Danilov lab models the tumor-supportive microenvironment in vitro, as well as studies drug resistant tumors in vivo. The lab has a track record investigating the function of the ubiquitin-proteasome system in cancer, and has studied proximal components of the UPS (E1 enzymes) as therapeutic targets in lymphoma. Moreover, the lab recently set out to advance understanding of the effect of targeted therapies on T cell function, thus hoping to inform progress in immuno-oncology.
 
Learn more about his research
Awards & Memberships
Awards

  • 2019, Abstract Achievement Award, 61st ASH Annual Meeting (Gordon & Danilov)

  • 2018, Leukemia & Lymphoma Society Scholar in Clinical Research

  • 2018, Abstract Achievement Award, 60th ASH Annual Meeting (Gordon & Danilov)

  • 2017, Participant, SWOG Integrated Translational Science Center Workshop, Cold Spring Harbor Laboratories, NY

  • 2017, Gebroe Family Lecture at the Lymphoma & Myeloma 2017, New York, NY

  • 2017, Abstract Achievement Awards, 59th ASH Annual Meeting (Best & Danilov

  • Gordon & Danilov)

  • 2016, Knight Cancer Institute Clinical Research Scholar

  • 2016, Abstract Achievement Award, 58th ASH Annual Meeting (Paiva & Danilov)

  • 2014, Lymphoma Research Foundation Clinical Investigator

  • 2013, Best Abstract, Young Investigator/XV International Workshop on CLL, Köln/Germany

  • 2013, Gazzaniga Family Prize for outstanding research at Dartmouth (Thesis Advisor to L.A.Humphries)

  • 2012, Abstract Achievement Award, 54th ASH Annual Meeting (Humphries & Danilov)
    2012, Participant, ASH Clinical Research Training Institute, La Jolla, CA

  • 2010, Excellence in Teaching Award, Medicine, Dartmouth-Hitchcock Medical Center

Memberships

  • 2017, Member, SWOG CLL Study Group

  • 2016, Member, SWOG Leukemia Working Group

  • 2014, Member, SWOG Lymphoma Working Group

Publications
Kittai AS, Best S, Thurlow B, Lam V, Hashiguchi T, Goodyear S, Persky DO, Okada C, Park B, Spurgeon S and Danilov AV. 2021. Entospletinib and obinutuzumab in patients with relapsed/refractory CLL and B-cell malignancies. Haematologica. doi: 10.3324/haematol.2020.270298.
 
Best S, Lam V, Liu T, Bruss N, Kittai A, Danilova OV, Murray S, Berger A, Pennock ND, Lind EF and Danilov AV. 2021. Immunomodulatory effects of pevonedistat, a Nedd8-activating enzyme inhibitor, in CLL. Leukemia. 35(1): 156-168.
 
Danilov AV, Persky DO. 2021. Incorporating acalabrutinib, a next-generation selective BTK inhibitor, into clinical practice for the treatment of hematologic malignancies. 2020. British Journal of Haematology. https://doi.org/10.1111/bjh.17184.
 
Evens AM, Danilov AV, …, Olszewski AJ and Alderuccio JP. 2021. Burkitt Lymphoma in the Modern Era: Real World Outcomes and Prognostication Across 30 US Cancer Centers. Blood. 137(3); 374-386.
 
Gordon MJ, Huang J, Chan RJ, Bhargava P and Danilov AV. 2021. Medical comorbidities in patients with chronic lymphocytic leukemia treated with idelalisib: analysis of two large randomized clinical trials. British J Haemtol. 192(4): 720-728.
 
Danilov AV, Spurgeon SE, Siddiqi T, Quinson AM, Maier D, Smith D and Brown JR. 2021. A Phase Ib, open label, dose escalation trial of the anti-CD37 monoclonal antibody, BI836826, in combination with ibrutinib in patients with relapsed/refractory CLL. Invest New Drugs. doi: 10.1007/s10637-020-01056-4
 
Danilov AV, Herbaux C, Walter H, Hillmen P, Rule S, Kio EA, Karlin L, Dyer MJ, Mitra S, Yi PC, Humeniuk R, Huang X, Zhou Z, Bhargava P, Jurgensmeier JM and Fegan C. 2020. Phase 1b study of tirabrutinib alone or in combination with idelalisib or entospletinib in previously treated CLL. Clinical Cancer Research. 26 (12): 2810-2818.
 
Kittai AS Gordon MJ, Mian A, Fitzgerald L, Bishop K, Stephens DM, Nagle SJ, Hill BT and Danilov AV. 2020. Comorbidities predict inferior survival in patients receiving chimeric antigen receptor T-cell therapy for DLBCL: A multicenter analysis. Biology of Blood and Marrow Transplantation. In press.
 
Sharman J, Yimer H, Boxer M, Di Bella N, Babu S, Li J, Mun Y and Danilov AV. 2020. Phase 2, multicenter GIBB study of obinutuzumab plus bendamustine in previously untreated patients with CLL. Leukemia & Lymphoma. In press. 
 
Eide CA, Kurtz SE, Kaempf A, Long N, Agarwal A, Tognon CE, Mori M, Druker BJ, Chang BH, Danilov AV and Tyner JW. 2020. Simultaneous kinase inhibition with ibrutinib and BCL2 inhibition with venetoclax offers a therapeutic strategy for acute myeloid leukemia. Nature Leukemia. doi: 10.1038/s41375-020-0764-6. 
 
Best SR, Hashiguchi T, Kittai A, Bruss N, Paiva C, Okada C, Liu T, Berger A and Danilov AV. 2019. Targeting ubiquitin-activating enzyme induces ER stress-mediated apoptosis in B-cell lymphoma cells. Blood Advances. 3(1): 51-62.
 
Hashiguchi T, Bruss N, Best S, Lam V, Danilova OV, Paiva C, Wolf J, Gilbert E, Okada C, Kaur P, Drew L, Cidado J, Hurlin P and Danilov AV. 2019. Cyclin-dependent kinase-9 is a therapeutic target in MYC-expressing diffuse large B-cell lymphoma. Molecular Cancer Therapeutics. 18(9): 1520-1532.
 
Nechiporuk T, Kurtz SE, Nikolova O, Liu T, Jones CL, D’Alessandro A, Culp-Hill R, d’Almeida A, Joshi SK, Rosenberg M, Tognon CE, Danilov AV, Druker BJ, Chang BH, McWeeney SK and Tyner JW. 2019. The TP53 apoptotic network is a primary mediator of resistance to BCL2 inhibition in AML cells. Cancer Discovery. 9 (7): 910-925.
 
Gordon M, Churnetski M, Alqahtani H, Rivera X, Kittai A, Amrock SM, James S, Hoff S, Manda S, Spurgeon SE, Choi M, Cohen JB, Persky D and Danilov AV. 2018. Comorbidities predict inferior outcomes in chronic lymphocytic leukemia treated with ibrutinib. Cancer. 124(15): 3192-3200.
 
Tyner JW, Tognon CE, Bottomly D, Wilmot B, Kurtz S, Savage S, Long N, Reister-Shulz A, Traer E, Abel M, ….., Danilov AV, ….., Druker BD. 2018. Functional genomic landscape of acute myeloid leukemia. Nature. doi: 10.1038/s41586-018-0623-z
Ratings & Reviews
Ratings and reviews below are gathered from the Press Ganey Clinician and Group Consumer Assessment of Healthcare Providers and Systems (CG CAHPS) survey. CG CAHPS is a standardized survey that is used to measure a patient's experience in the physician office setting. Ratings are an average of all responses to questions about a provider's care, with 5 stars being the highest.
Ratings
4.9
Show respect for what you say
4.9
Provider listen carefully to you
4.8
Know important info medical history
4.8
Spend enough time with you
4.8
Rate provider 0-10
4.8
Recommend this provider office
4.8
Provider explain in way you understand
Reviews
07/04/22
I hope I can put very good when the treatment is finished. - Verified patient
05/09/22
I was very happy with the service I received. - Verified patient
05/09/22
My experience was very positive I will recommend it to anyone. - Verified patient
03/30/22
Dr. Alexy is wonderful, smart, practical and really knows his stuff - Verified patient
03/21/22
Great and knowledgeable doctor Danilov - Verified patient